3352-69-0 Usage
Description
4-Desacetyl Vinblastine is a chemical compound derived from the Vinca alkaloids, which are naturally occurring substances found in the Madagascar periwinkle plant. It is an off-white solid with potent antitumor properties, making it a valuable pharmaceutical candidate for cancer treatment.
Uses
Used in Anticancer Applications:
4-Desacetyl Vinblastine is used as an antitumor agent for the treatment of prostate cancer. It targets and disrupts the microtubules within cancer cells, inhibiting their ability to divide and grow, ultimately leading to cell death.
Additionally, 4-Desacetyl Vinblastine serves as a pro-drug of Vinblastine, a well-known chemotherapeutic agent. This means that it is metabolized or converted within the body to produce the active form of Vinblastine, which can then exert its anti-cancer effects more effectively.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Desacetyl Vinblastine is used as a precursor in the synthesis of other Vinca alkaloid-based drugs. Its chemical properties and antitumor activity make it a crucial component in the development of novel cancer therapies and drug formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 3352-69-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,5 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3352-69:
(6*3)+(5*3)+(4*5)+(3*2)+(2*6)+(1*9)=80
80 % 10 = 0
So 3352-69-0 is a valid CAS Registry Number.
InChI:InChI=1/C44H56N4O8.H2O4S/c1-7-40(52)22-26-23-43(38(50)55-5,34-28(14-18-47(24-26)25-40)27-12-9-10-13-31(27)45-34)30-20-29-32(21-33(30)54-4)46(3)36-42(29)16-19-48-17-11-15-41(8-2,35(42)48)37(49)44(36,53)39(51)56-6;1-5(2,3)4/h9-13,15,20-21,26,35-37,45,49,52-53H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t26-,35+,36-,37-,40+,41-,42?,43+,44+;/m1./s1
3352-69-0Relevant articles and documents
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity
Brady, Stephen F.,Pawluczyk, Joseph M.,Lumma, Patricia K.,Feng, Dong-Mei,Wai, Jenny M.,Jones, Raymond,DeFeo-Jones, Deborah,Wong, Bradley K.,Miller-Stein, Cynthia,Lin, Jiunn H.,Oliff, Allen,Freidinger, Roger M.,Garsky, Victor M.
, p. 4706 - 4715 (2007/10/03)
Chemotherapy of prostate cancer with antimitotic agents such as vinblastine and doxorubicin is only marginally effective, due to dose-limiting systemic toxicity. Herein we report the development of peptidyl conjugate 5 of the cytotoxic agent vinblastine (
Biosynthesis of the dimeric indole alkaloids. II. Catharanthine as a precursor of vincaleukoblastine
Hassam,Hutchinson
, p. 1681 - 1684 (2007/10/10)
-
